

QCDR Measure:

AAO-13: Diabetic Macular Edema: Loss of Visual Acuity

National Quality Strategy Domain:

Effective Clinical Care

Measure Type:

Outcome

Description:

Percentage of patients with a diagnosis of diabetic macular edema with of loss of less than 0.3 logMar of visual acuity within the past 12 months.

Instructions:

This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with diabetic macular edema (in either one or both eyes) will submit this measure.

Denominator:

All patients aged 18 years or older with a diagnosis of diabetic macular edema including documentation of the laterality (OD, OS, OU) who have received anti-VEGF injections, intravitreal injections or laser photocoagulation therapy.

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of diabetic macular edema

- Diabetic macular edema (ICD-10: E08.311, E08.321, E08.331, E08.341, E08.351, E09.311, E09.321, E09.331, E09.341, E09.351, E10.311, E10.321, E10.331, E10.341, E10.351, E11.311, E11.321, E11.331, E11.341, E11.351, E13.311, E13.321, E13.331, E13.341, E13.351)

AND

Four or more recorded visual acuity values within the past 12 months

AND

Treatment with Anti-VEGF Agents OR Intravitreal Steroids OR Laser Photocoagulation

- Bevacizumab (Avastin®) injections (CPT: 67028 & HCPCS: J9035; CPT: 67028 & HCPCS: J3490; CPT: 67028 & HCPCS: J3590; CPT: 67028 & HCPCS: C9257)
- Ranibizumab (Lucentis®) injections (CPT: 67028 & HCPCS: J2778)
- Aflibercept (EYLEA®) injections (CPT: 67028 & HCPCS: J0178)

OR

- Fluocinolone acetonide (Iluvien) injections (CPT: 67028 & HCPCS: J7311)
- Dexamethasone (Ozurdex) injections (CPT: 67028 & HCPCS: J7312)
- Triamcinolone (Kenalog) injections (CPT: 67028 & HCPCS: J3301)
- Triamcinolone acetonide (Triesence) injections (CPT: 67028 & HCPCS: J3300)

OR

- Laser photocoagulation (CPT: 67210, 67228)

Denominator Exclusions:

Patients with ophthalmic complications of diabetic retinopathy including neovascular glaucoma, traction retinal detachment, vitreous hemorrhage, history of vitreous surgery, history of retinal surgery, development of retinopathy in fellow eye. (ICD-10-CM: H40.89, H33.40, H33.41, H33.42, H33.43, H43.10, H43.11, H43.12, H43.13)

Numerator:

Patients with four or more recorded visual acuity values within the past 12 months; loss of visual acuity less than 0.3 logMar. Visual acuity of the eye(s) being treated will be evaluated.

Numerator Options:

| | |
|----------------------|---|
| Performance Met: | Patients who achieved a loss of $\leq 0.3\log\text{Mar}$ in the past 12 months |
| Performance Not Met: | Patients who did not achieve a loss of $\leq 0.3\log\text{Mar}$ in the past 12 months |

Improvement Notation:

Higher score indicates better performance